Navigation Links
Biopure Announces 2007 Third Quarter Financial Results
Date:8/23/2007

CAMBRIDGE, Mass., Aug. 23 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) today announced its financial results for the third fiscal quarter ended July 31, 2007. For the quarter, the company reported a net loss of $6.4 million, or $0.08 per common share, compared with a net loss of $6.6 million, or $0.16 per common share, for the corresponding period in 2006. Class A common shares outstanding on July 31, 2007 and 2006 were 77,960,126 and 41,789,370, respectively.

Revenues

Total revenues for the third quarter of 2007 were $550,000, including $470,000 from sales of the company's veterinary product Oxyglobin(R) and $58,000 from sales of Hemopure(R) in South Africa. Total revenues for the same period in 2006 were $396,000, including $312,000 from Oxyglobin sales and $1,000 from sales of Hemopure(R). The increase in Hemopure sales reflects the company's marketing efforts and increasing use of the product. Oxyglobin revenues increased during the third fiscal quarter of 2007 compared to 2006 due to a higher average selling price for product sold in the U.S.

Cost of revenues was $3.1 million for the third quarter of fiscal 2007, compared to $2.9 million for the same period in 2006. Cost of revenues includes costs of both Oxyglobin and Hemopure. The increase is mainly due to higher salaries expense and plant costs.

Expenses

Research and development expenses were $1.6 million for the third quarter of fiscal 2007 compared to $1.8 million during the same period in 2006. Expenses during the third fiscal quarter of 2006 include costs related to the marketing authorization application the company submitted to the United Kingdom regulatory authority in 2006, for which there are no comparable
'/>"/>

SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... NORWALK, Conn. , Aug. 27, 2014  UBM ... , a leading online community for medical imaging professionals, ... Association for Medical Imaging Management,s 2014 Annual Meeting ... the conference coverage: , 11 Principles ... management can lead to greater profitability. , ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- Emergency ... design, blended emergency medical training and response technologies, ... defibrillator) training from the Department of Homeland ... Reserve 81 st Regional Support Command ... contract includes nationwide CPR/AED/First Aid training. The Army ...
(Date:8/27/2014)... , Aug. 27, 2014   Auxilium Pharmaceuticals , Inc. ... biopharmaceutical company, today announced that certain members of the ... Healthcare Conference to be held September 8-10, 2014 in ... , Chief Executive Officer and President, is scheduled to ... portfolio at 10:55 a.m. ET on Wednesday, September 10, ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3
... Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in ... it has dosed the first patient with recent onset ... ongoing Phase I study of QPI-1007, the Company,s proprietary ... The Phase I open-label, dose-escalation study was initiated ...
... PHILADELPHIA, Oct. 20 ERT (Nasdaq: ... for the third quarter 2010 on Thursday, November 4, 2010, ... host a conference call at 5:00 PM EDT that day. ... dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 ...
Cached Medicine Technology:Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 2Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
(Date:8/27/2014)... Will Holbrook, CP LP, has joined ... over 15 years of experience in the prosthetics field. ... with a Bachelor of Science degree with a major ... received his graduate degree in prosthetics at Northwestern University ... Will join us at Fourroux,” says Keith Watson, owner ...
(Date:8/27/2014)... 27, 2014 (HealthDay News) -- A new genetic discovery ... fight the bowel disorder, researchers report. The ... affect how their genes work, and said these changes ... raising the possibility of a simple diagnostic test for ... disease develops and suggest possible gene targets for new ...
(Date:8/27/2014)... The American Brain Tumor Association is ... Research Fellowships and 2014-2015 Discovery Grant Awards. Through the ... the field with talented, bright young investigators who have ... effects, diagnosis and treatment of brain tumors. This year’s ... the potential to advance the understanding and treatment of ...
(Date:8/27/2014)... Albany, New York (PRWEB) August 27, 2014 ... published by Transparency Market Research "Ablation Technologies Market ... Technologies: Radiofrequency, Light/Laser, Electrical, Ultrasound, Microwave, Cryotherapy) - ... Forecast, 2014 - 2020," the global ablation technologies ... 2013 and is estimated to reach a market ...
(Date:8/27/2014)... Center for Leadership in Disability (CLD) has received ... Child Health Bureau of the Health Resources and ... Plan for Georgia, aimed at improving services for ... In preparing for this project, CLD worked with ... from across Georgia. The resulting plan addresses priorities ...
Breaking Medicine News(10 mins):Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5
... in the last one month in Deomali and its ... officer N Singh said today. // ,Singh ... war footing to bring the situation under control., ... claimed death of 20 people in 15 days and ...
... of Georgia say that even if the surgery has gone ... of cardiovascular disease// and possibly cancer for several weeks post-operatively. ... is that when bad things happen down the road, months, ... in the past, just attribute it to the natural course ...
... today said it has entered into an agreement with ... of Foot and Mouth Disease (FMD) vaccine developed by ... the agreement, we will produce and market the vaccine ... meet the requirements of the domestic market and if ...
... 6. Even as asthma patients from different parts of ... fish medicine, rationalists have stepped up their campaign against ... of rationalists, has again urged the Andhra Pradesh government ... 'drug' was based on 'superstition'. ,The Bathini family, ...
... activity of a protein called NFATc1 tends to cause ... treat osteoporosis //- HHMI investigator Gerald Crabtree and HHMI ... bone is constantly being formed and being broken down ... cells called osteoblasts replenish it. ,‘Ideally, ...
... illness, which was under-diagnosed till now was found to ... thought before//. Intermittent Explosive Disorder or Rage disorder is ... outbursts. This illness if left untreated may also lead ... ,Intermittent Explosive Disorder attacks are out of proportion to ...
Cached Medicine News:Health News:Well-Planned Surgeries Also Carry Health Risks 2Health News:Well-Planned Surgeries Also Carry Health Risks 3Health News:'Fishy' Medicine Stirs Controversy 2Health News:'Fishy' Medicine Stirs Controversy 3Health News:Osteoporosis – A New Treatmen 2Health News:Osteoporosis – A New Treatmen 3Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 2Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 3
... CVA for CELL-DYN are assayed linearity control ... and to verify patient reportable range of ... also measure the linear performance of the ... have customized ranges appropriate for each instrument ...
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
... Proprietary EX.P.R.T. Release ... jumping,, No stent shortening,, Unique anatomically ... in the carotid bifurcation,, 0.014 Rapid ... crossing profile and flexible atraumatic tip,, ...
... Para 5X is a whole blood ... Pentra 60C+, 80 and 120, and the ... product offers a unique white cell differential, ... the algorithms on the systems. The product ...
Medicine Products: